|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smith MW, Yue ZN, Korth MJ, Do HA, Boix L,
Fausto N, Bruix J, Carithers RL Jr and Katze MG: Hepatitis C virus
and liver disease: Global transcriptional profling and
identifcation of potential markers. Hepatology. 38:1458–1467. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Di Bisceglie AM, Bruix J,
Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M,
Talwalkar J, et al: Design and endpoints of clinical trials in
hepatocellular carcinoma. J Natl Cancer Inst. 100:698–711. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Talwalkar JA and Gores GJ: Diagnosis and
staging of hepatocellular carcinoma. Gastroenterology. 127(5 Suppl
1): S126–S132. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim DH and Rossi JJ: Strategies for
silencing human disease using RNA interference. Nat Rev Genet.
8:173–184. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gartel AL and Kandel ES: RNA interference
in cancer. Biomol Eng. 23:17–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Castanotto D and Rossi JJ: The promises
and pitfalls of RNA-interference-based therapeutics. Nature.
457:426–433. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Javaherian K, Liu JF and Wang JC:
Nonhistone proteins HMG1 and HMG2 change the DNA helical structure.
Science. 199:1345–1346. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lotze MT and Tracey KJ: High-mobility
group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal.
Nat Rev Immunol. 5:331–42. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sims GP, Rowe DC, Rietdijk ST, Herbst R
and Coyle AJ: HMGB1 and RAGE in infammation and cancer. Annu Rev
Immunol. 28:367–88. 2010. View Article : Google Scholar
|
|
11
|
Tang D, Kang R, Zeh HJ III and Lotze MT:
High-mobility group box 1 and cancer. Biochim Biophys Acta.
1799:131–40. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kostova N, Zlateva S, Ugrinova I and
Pasheva E: The expression of HMGB1 protein and its receptor RAGE in
human malignant tumors. Mol Cell Biochem. 337:251–58. 2010.
View Article : Google Scholar
|
|
13
|
Park JS, Gamboni-Robertson F, He Q,
Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama
I, Banerjee A, et al: High mobility group box 1 protein interacts
with multiple Toll-like receptors. Am J Physiol Cell Physiol.
290:C917–924. 2006. View Article : Google Scholar
|
|
14
|
Yu M, Wang H, Ding A, Golenbock DT, Latz
E, Czura CJ, Fenton MJ, Tracey KJ and Yang H: HMGB1 signals through
toll-like receptor (TLR) 4 and TLR2. Shock. 26:174–79. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wolfson RK, Chiang ET and Garcia JG: HMGB1
induces human lung endothelial cell cytoskeletal rearrangement and
barrier disruption. Microvasc Res. 81:189–97. 2011. View Article : Google Scholar
|
|
16
|
Larocca C, Cohen JR, Fernando RI, Huang B,
Hamilton DH and Palena C: An autocrine loop between TGF-β1 and the
transcription factor brachyury controls the transition of human
carcinoma cells into a mesenchymal phenotype. Mol Cancer Ther.
12:1805–815. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang JD, Harmsen WS, Slettedahl SW,
Chaiteerakij R, Enders FT, Therneau TM, Orsini L, Kim WR and
Roberts LR: Factors that affect risk for hepatocellular carcinoma
and effects of surveillance. Clin Gastroenterol Hepatol.
9:617–623.e1. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
El-Nahas AM: Plasticity of kidney cells:
Role in kidney remodeling and scarring. Kidney Int. 64:1553–563.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sato M, Shames DS and Hasegawa Y: Emerging
evidence of epithelial-to-mesenchymal transition in lung
carcinogenesis. Respirology. 17:1048–059. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu Z, Dou C, Jia Y, Li Q, Zheng X, Yai Y,
Liu Q and Song T: RIG-I suppresses the migration and invasion of
hepatocellular carcinoma cells by regulating MMP9. Int J Oncol.
46:1710–720. 2015.PubMed/NCBI
|
|
21
|
Rudmik LR and Magliocco AM: Molecular
mechanisms of hepatic metastasis in colorectal cancer. J Surg
Oncol. 92:347–59. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kumar S and Weaver VM: Mechanics,
malignancy and metastasis: The force journey of a tumor cell.
Cancer Metastasis Rev. 28:113–27. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Naghavi MH, Nowak P, Andersson J,
Sönnerborg A, Yang H, Tracey KJ and Vahlne A: Intracellular high
mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed
transcription in a promoter-and cell-specifc manner. Virology.
314:179–189. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ueda M, Takahashi Y, Shinden Y, Sakimura
S, Hirata H, Uchi R, Takano Y, Kurashige J, Iguchi T, Eguchi H, et
al: Prognostic signifcance of high mobility group box 1 (HMGB1)
expression in patients with colorectal cancer. Anticancer Res.
34:5357–5362. 2014.PubMed/NCBI
|
|
25
|
Li LC, Gao J and Li J: Emerging role of
HMGB1 in fbrotic diseases. J Cell Mol Med. 18:2331–2339. 2014.
View Article : Google Scholar : PubMed/NCBI
|
